

moeity (9, 10). The C₃-CH₃ proton signal has a δ value of ~ 2.80 for the aliphatic series **13B**-**16B**, whereas it is only ~ 2.48 for the aromatic analogue **12B**.

N-(3-Methyl-2-quinoxaloyl) Amines (1C-16C). These were obtained by deoxygenation of the corresponding quinoxaline 1,4-dioxides (0.10 mol) with excess Na₂S₂O₄ (69.6 g, 0.40 mol) in refluxing aqueous EtOH, following standard procedures (15). The title compounds are precipitated from the reaction mixture by cooling and dilution with water, collected, dried, and crystallized from the appropriate solvent. Yields of the pure quinoxalines were in the range 45-70%. The mass spectra of **1C**-**16C** show characteristic peaks at the following m/z values: M⁺, 171, 143. The (M - CH₂OH)⁺ ions are also observed for **12C**-**16C**. The ¹H NMR spectra (in Me₂SO-*d*₆) are in agreement with the assigned structures. The C₃-CH₃ δ value is ~ 2.90 for **12C**-**16C**.

Acknowledgment

We thank Professor C. H. Hassall (Director of Research, La Roche, England) for the biological tests and for his interest in this work.

Registry No. **1A**, 63664-38-0; **1B**, 88996-65-0; **1C**, 88996-79-6; **2A**, 88996-62-7; **2B**, 88996-66-1; **2C**, 88996-80-9; **3A**, 58102-37-7; **3B**, 88996-67-2; **3C**, 88996-81-0; **4A**, 63664-40-4; **4B**, 88996-68-3; **4C**, 88996-82-1; **5A**, 63664-41-5; **5B**, 88996-69-4; **5C**, 88996-83-2; **6A**, 63664-42-6; **6B**, 88996-70-7; **6C**, 88996-84-3; **7A**, 64401-27-0; **7B**, 88996-71-8; **7C**, 88996-85-4; **8A**, 64401-28-1; **8B**, 88996-72-9; **8C**, 88996-86-5; **9A**, 63664-39-1; **9B**, 88996-73-0; **9C**, 88996-87-6; **10A**, 63701-36-0; **10B**, 81485-17-8; **10C**, 88996-88-7; **11A**, 63664-37-9; **11B**, 89063-57-0; **11C**, 89063-58-1; **12A**, 63664-36-8; **12B**, 88996-74-1; **12C**, 88996-89-8; **13A**, 64401-30-5; **13B**, 88996-75-2; **13C**, 88996-90-1; **14A**,

63664-35-7; **14B**, 88996-76-3; **14C**, 88996-91-2; **15A**, 88996-63-8; **15B**, 88996-77-4; **15C**, 88996-92-3; **16A**, 88996-64-9; **16B**, 88996-78-5; **16C**, 88996-93-4; [*R*-(*R**,*S**)]-MeNHCH(CH₃)CH(OH)Ph, 299-42-3; (\pm)-(*R**,*S**)-MeNHCH(CH₃)CH(OH)Ph, 90-81-3; diketene, 674-82-8; (*S*)-2-amino-3-methylbutanol, 2026-48-4; (*S*)-2-amino-4-methylpentanol, 7533-40-6; [*S*-(*R**,*S**)]-2-amino-3-methylpentanol, 88996-94-5; 3-(2-aminoethyl)indole hydrochloride, 343-94-2; 4-(2-aminoethyl)imidazole hydrochloride, 55-36-7; 1-adamantanamine hydrochloride, 665-66-7; 2-adamantanamine hydrochloride, 10523-68-9; D-(+)-glucosamine hydrochloride, 66-84-2; benzo-furoxan, 674-82-8.

Literature Cited

- Ochia, E. "Aromatic Amine Oxides"; Elsevier: Amsterdam, 1967.
- Katritsky, A. H.; Lagowski, J. M. "Chemistry of the Heterocyclic N-Oxides"; Academic Press: New York, 1971.
- Pfizer, Inc., U.S. Patent 3948911, 1976.
- Pfizer Inc., U.S. Patent 4007184, 1977.
- Pfizer Inc., U.S. patent 4039540, 1977.
- A.G. Ciba-Geigy, German Patent 2701707, 1977.
- Research Corp., British Patent 1308370, 1973.
- Haddadin, M. J.; Issidorides, C. H. *Heterocycles* **1976**, *4*, 767-816.
- EL-Abadelah, M. M.; Sabri, S. S.; Nazer, M. Z.; Za'ater, M. F. *Tetrahedron* **1976**, *32*, 2931-8.
- EL-Abadelah, M. M.; Sabri, S. S.; Tashtoush, H. I. *Tetrahedron* **1979**, *35*, 2571-6.
- Henry, J. B. "Clinical Diagnosis and Management by Laboratory Methods"; Saunders: Philadelphia, PA, 1979; Vol. II, p 1622.
- Vogl, O.; Pöhm, M. *Monatsh. Chem.* **1952**, *83*, 541-3.
- Sabri, S. S.; EL-Abadelah, M. M.; Za'ater, M. F. *J. Chem. Soc., Perkin Trans. 1* **1977**, 1356-9.
- Mallory, F. M. In "Organic Synthesis"; Wiley: New York, 1967; Collect. Vol. IV, p 74.
- Haddadin, M. J.; Zahr, G. E.; Rawdah, T. N.; Chelhot, N. C.; Issidorides, C. H. *Tetrahedron* **1974**, *30*, 659-66.

Received for review August 24, 1983. Accepted October 26, 1983. We gratefully acknowledge the Research Committee of Jordan University and the Arab Pharmaceutical Co. (Amman) for financial support.

Potential Central Nervous System Active Agents. 3. Synthesis of Some Substituted Benzamides and Phenylacetamides

Vincent C. Agwada

Department of Chemistry, Faculty of Physical Sciences, University of Nigeria, Nsukka, Nigeria

The preparation and spectral properties (IR, ¹H NMR) are given for 45 benzamides and 10 phenylacetamides substituted on nitrogen with allyl, benzhydryl, benzyl, or cyclopropyl groups, and variously substituted on the acyl part with halo, methoxyl, methyl, or nitro groups. The benzamide derivatives were synthesized by the Schotten-Baumann method, and the phenylacetamide derivatives were prepared by heating the appropriate *N*-benzhydrylammonium salt in *o*-xylene. Thirty-one of the compounds are new.

In the preceding communications (1, 2) the synthesis and the spectroscopic properties (IR, mass spectra, ¹H NMR) of several aromatic *N*-benzyl amides were reported. Presented in the current communication are the synthesis and the spectroscopic data for 45 benzamides and 10 phenylacetamides substituted on nitrogen with allyl, benzhydryl, benzyl, or cyclopropyl groups, and variously substituted on the acyl part with halo, methoxyl, methyl, or nitro groups. The benzamide derivatives were prepared by the Schotten-Baumann method in anhydrous benzene, and the phenylacetamide derivatives were

synthesized from their corresponding *N*-benzhydrylammonium salts in boiling *o*-xylene as has been described earlier (1). With the exception of compounds Ia, VIa,b,h, and VIIa, all derivatives bearing the *N*-benzhydryl and *N*-cyclopropyl groups described herein are previously unreported. Compounds IIb,g, IIIId, and Vb,e,f, bearing the *N*-allyl, *N,N*-diallyl, or *N,N*-dibenzyl groups, are also unreported. The spectroscopic data (IR, ¹H NMR) not hitherto described in the literature are reported in this publication. The experimental and IR data on all the compounds are summarized in Table I, and those of the ¹H NMR data are given in Table II. Satisfactory elemental analyses ($\pm 0.4\%$ for C, H, N, and halogens, where present) were obtained for all compounds.

The structures of these amides were established on the basis of analytical and spectroscopic data. These compounds have been submitted for biological screening, and results will be published elsewhere.

Experimental Section



The reagents used in these experiments were of commercial grade. Mass spectra were determined on a Varian-MAT CH-5 spectrometer at 70 eV, by Messrs. J. C. Cook and M. Cochran, Mass Spectroscopy Laboratory, University of Illinois, Urbana

Table I. Experimental and IR Data of Some Substituted Benzamides and Phenylacetamides

compd	mol formula	M ⁿ . ^a	yield, %	exptl	reported	mp, °C	IR, cm ⁻¹			
							NH	amide band		others
								I	II	
Ia	C ₁₀ H ₁₁ NO	161	76	99	97.5-98 (3), 100.6-101 (4)	3245	1623	1557	1567	
Ib	C ₁₁ H ₁₃ NO	175	82	110-112		3310	1633	1528	1613 sh, 1573, 1506	
Ic	C ₁₁ H ₁₃ NO ₂	191	93	138-140		3280	1623	1542	1610, 1562 sh, 1503	
Id	C ₁₀ H ₁₀ FNO	179	79 ^b	77-78		3282	1647	1630	1617	
Ie	C ₁₀ H ₁₀ FNO	179	60	84-84.5		3305	1638	1520	1582	
If	C ₁₀ H ₁₀ FNO	179	95 ^c	118-119		3275	1642	1543 sh, 1523	1612, 1573 sh	
Ig	C ₁₀ H ₁₀ CINO	195/197	81 ^c	119-121		3250	1633	1549	1609 sh, 1595	
Ih	C ₁₀ H ₁₀ CINO	195/197	95	135		3285	1643, 1633	1530	1593	
Ii	C ₁₀ H ₁₀ BrNO	239/241	71	120		3268	1643	1525	1613 sh, 1590	
Ij	C ₁₀ H ₁₀ INO	287	<i>d</i>	148		3270	1645	1527	1615 sh, 1585	
Ik	C ₁₀ H ₁₀ N ₂ O ₃	206	69 ^e	153-154		3311	1647	1528	1604 sh, 1519, 1502	
Il	C ₁₀ H ₁₀ N ₂ O ₃	206	82 ^e	180-182		3290	1642	1545 sh, 1532	1598, 1518	
Ila	C ₁₁ H ₁₃ NO	175	92	76-77 ^c		3285	1632	1542	1503	
Ilb	C ₁₀ H ₁₀ FNO	179	78	45-46 ^c		3310	1636	1542	1586	
Ilc	C ₁₀ H ₁₀ FNO	179	73	65-66 ^c		3320	1633	1542	1603, 1591	
Ild	C ₁₀ H ₁₀ CINO	195/197	80	65-66 ^f	67-68 (5), 63-67 (6)	3260	1638	1527	1590	
Ile	C ₁₀ H ₁₀ CINO	195/197	81	50	43-45 (7)	3308	1633	1526	1595, 1568	
Ilf	C ₁₀ H ₁₀ CINO	195/197	92	72-73 ^c	73 (8)	3280	1628	1528	1593	
Ilg	C ₁₀ H ₁₀ BrNO	239/241	<i>d</i>	88-89 ^c		3260	1640	1529	1588	
Ihh	C ₁₀ H ₁₀ N ₂ O ₃	206	95	55 ^e		3265	1639	1540 sh	1518	
Ihi	C ₁₀ H ₁₀ N ₂ O ₃	206	99 ^e	119-120		3320	1650, 1638	1540	1597, 1513	
Ihla	C ₁₀ H ₁₀ N ₂ O ₃	215	77 ^g	50-52		1631				
Ihla	C ₁₄ H ₁₇ NO ₂	231	86 ^g	40		1623			1603, 1591	
Ihla	C ₁₃ H ₁₆ CINO	235/237	78 ^g	57		1633			1595	
Ihld	C ₁₃ H ₁₄ N ₂ O ₃	246	47 ^c	53-53.5		1637			1569, 1514	
Iva	C ₁₄ H ₁₇ FNO	229	82	68-69	39-40 (9)	3268	1636	1528	1613	
Ivb	C ₁₄ H ₁₇ N ₂ O ₃	256	77	138-139 ^h	122-123 (10)	3278	1635	1550	1614, 1522	
Va	C ₂₁ H ₁₉ NO	301	98	113	112-112.8 (11, 12), 113-114 (13), 113.5- 114.5 (14)		1620		1570	
Vb	C ₂₂ H ₂₁ NO	315	56	98			1627			
Vc	C ₂₂ H ₂₁ NO ₂	331	88	121-122 ^c	121-122 (14)		1633		1604	
Vd	C ₂₁ H ₁₉ FNO	319	91	<i>i</i>			1630		1610, 1580	
Ve	C ₂₁ H ₁₈ FNO	319	87	97 ^c			1629		1602, 1585	
Vf	C ₂₁ H ₁₈ CINO	335/337	91	116-117 ^c			1637		1590, 1583	
Vg	C ₂₁ H ₁₈ CINO	335/337	95	125-127	112-113.5 (14)		1637		1568	
Vh	C ₂₁ H ₁₈ CINO	335/337	65	110 ^c	108-109 (14)		1640		1593	
Vi	C ₂₁ H ₁₈ N ₂ O ₃	346	84	109 ^c	104-105 (15)		1637		1575, 1541, 1526	
Vj	C ₂₁ H ₁₈ N ₂ O ₃	346	86	129 ^h			1636		1600, 1515	
Vla	C ₂₀ H ₁₇ NO	287	92 ^e	167	167-169 (16), 167, 173 (17), 171-172.4 (18, 19), 175-176 (20), 185 (21)	3308	1633	1510	1595, 1583	
Vlb	C ₂₁ H ₁₉ NO ₂	317	81 ^e	193-195	198-199 (20)		1635		1618, 1578	
Vlc	C ₂₀ H ₁₆ FNO	305	74 ^e	176-177			1640		1615, 1583	
Vld	C ₂₀ H ₁₆ FNO	305	91	118.5			1643		1605	
Vle	C ₂₀ H ₁₆ CINO	321/323	79 ^e	163-164			1642		1590	
Vlf	C ₂₀ H ₁₆ CINO	321/323	88 ^e	220			1640		1593	
Vlg	C ₂₀ H ₁₆ N ₂ O ₃	332	65	203-204			1634		1570 sh	

VIIh	$C_{20}H_{16}N_2O_3$	332	71 ^e	250-251	223-224 (20)	1635	1515	1603, 1538
VIIa	$C_{21}H_{19}NO$	301	80 ^e	162-163	161.2-162.4 (19), 164-165 (20)	1652	1522	1598, 1584
VIIb	$C_{22}H_{21}NO$	315	60 ^e	174		1650	1530	1598, 1584
VIIc	$C_{22}H_{21}NO$	315	89 ^e	193		3270 ^f	1530	1600 sh
VIIId	$C_{22}H_{21}NO_2$	331	76 ^e	147-148		3290	1529	1600, 1585
VIIe	$C_{22}H_{21}NO_2$	331	66 ^h	125-127		3310	1647	1610 sh, 1584
VIIIf	$C_{22}H_{21}NO_2$	331	70 ^e	175		3265	1543, 1535	1608 sh, 1508
VIIg	$C_{21}H_{18}FNO$	319	<i>d, h</i>	152		3295	1647	1597
VIIh	$C_{21}H_{18}ClNO$	335/337	80 ^e	185		3287	1530	1594
VIIi	$C_{21}H_{18}ClNO$	335/337	85 ^e	163		3250	1545	1602
VIIj	$C_{21}H_{18}BrNO$	379/381	78 ^e	164-165		3310	1528	1603 sh, 1583

^a The mass spectra of these amides will be published later. ^b From petroleum ether (60-80 °C). ^c From benzene-petroleum ether. ^d Quantitative yield. ^e From acetone-benzene. ^f From acetone-petroleum ether. ^g Crystallized neat. ^h From acetone. ⁱ Wide melting range (80-90 °C (14)). ^j Spectrum obtained from a Perkin-Elmer Infracord Model 137.



PART B

no.	R	R'	R''	R	R'	R''	no.	R	no.	R
Ia	H	H	C_3H_5 cyclopropyl	4-OMe 4-Cl 2-NO ₂	$CH_2CH=CH_2$ $CH_2CH=CH_2$ $CH_2CH=CH_2$	$CH_2CH=CH_2$ $CH_2CH=CH_2$ $CH_2CH=CH_2$	VIIa	H	VIIIf	R
Ib	4-Me	H	C_3H_5	2-F 2-NO ₂	H	ArCH ₂	VIIb	2-Me	VIIg	4-OMe
Ic	4-OMe	H	C_3H_5	H	H	ArCH ₂	VIIc	4-Me	VIIh	4-F
Id	2-F	H	C_3H_5	4-Me	ArCH ₂	ArCH ₂	VIIId	2-OMe	VIIi	2-Cl
Ie	3-F	H	C_3H_5	4-OMe	ArCH ₂	ArCH ₂	VIIe	3-OMe	VIIj	4-Cl
If	4-F	H	C_3H_5	2-F	ArCH ₂	ArCH ₂				4-Br
Ig	2-Cl	H	C_3H_5	4-F	ArCH ₂	ArCH ₂				
Ih	4-Cl	H	C_3H_5	2-Cl	ArCH ₂	ArCH ₂				
II	2-Br	H	C_3H_5	3-Cl	ArCH ₂	ArCH ₂				
Ij	2-I	H	C_3H_5	4-Cl	ArCH ₂	ArCH ₂				
Ik	2-NO ₂	H	C_3H_5	2-NO ₂	ArCH ₂	ArCH ₂				
II	4-NO ₂	H	C_3H_5	4-NO ₂	ArCH ₂	ArCH ₂				
IIa	4-Me	H	$CH_2CH=CH_2$	H	H	Ar ₂ CH				
IIb	3-F	H	$CH_2CH=CH_2$	4-OMe	H	Ar ₂ CH				
IIc	4-F	H	$CH_2CH=CH_2$	2-F	H	Ar ₂ CH				
IIId	2-Cl	H	$CH_2CH=CH_2$	4-F	H	Ar ₂ CH				
IIe	3-Cl	H	$CH_2CH=CH_2$	4-F	H	Ar ₂ CH				
IIf	4-Cl	H	$CH_2CH=CH_2$	2-Cl	H	Ar ₂ CH				
IIg	2-Br	H	$CH_2CH=CH_2$	4-Cl	H	Ar ₂ CH				
IIh	2-NO ₂	H	$CH_2CH=CH_2$	2-NO ₂	H	Ar ₂ CH				
IIi	4-NO ₂	H	$CH_2CH=CH_2$	4-NO ₂	H	Ar ₂ CH				
IIIa	4-Me	$CH_2CH=CH_2$	$CH_2CH=CH_2$	4-OMe	H	Ar ₂ CH				

Table II. ^1H NMR Spectral Data of Some Substituted Benzamides and Phenylacetamides^a

compd	chemical shifts, δ
Ia	7.77 (m, 2, ArH), 7.33 (m, 3, ArH; + 1 NH), 2.88 (m, 1, methine), 0.80 (m, 1, methylene), 0.63 (m, 3, methylene)
Ib	7.70 (d, 2, $J = 8$, ArH), 7.20 (d, 2, $J = 8$, ArH), 6.65 (br, 1, NH), 2.87 (m, 1, methine), 2.83 (s, 3, ArCH ₃), 0.87 (m, 1, methylene), 0.70 (m, 3, methylene)
Ic	7.77 (d, 2, $J = 8$, ArH), 6.83 (d, 2, $J = 8$, ArH; + 1 NH), 3.78 (s, 3, ArOCH ₃), 2.87 (m, 1, methine), 0.80 (m, 1, methylene), 0.63 (m, 3, methylene)
Id	7.80-8.30 (m, 1, ArH), 6.50-7.70 (m, 3, ArH; + 1 NH), 2.93 (m, 1, methine), 0.90 (m, 1, methylene), 0.70 (m, 3, methylene)
Ie	7.97 (br, 1, NH), 6.80-7.80 (m, 4, ArH), 2.87 (m, 1, methine), 0.73 (m, 4, methylene)
If	7.50-8.10 (m, 2, ArH), 6.70-7.50 (m, 2, ArH; + 1 NH), 2.87 (m, 1, methine), 0.82 (m, 1, methylene), 0.70 (m, 3, methylene)
Ig	7.00-7.80 (m, 4, ArH), 6.70 (br, 1, NH), 2.90 (m, 1, methine), 0.88 (m, 1, methylene), 0.70 (m, 3, methylene)
Ih	7.77 (d, 2, $J = 8$, ArH), 7.30 (d, 2, $J = 8$, ArH; + 1 NH), 2.87 (m, 1, methine), 0.82 (m, 1, methylene), 0.70 (m, 3, methylene)
Ii	7.23 (m, 4, ArH), 6.46 (br, 1, NH), 2.90 (m, 1, methine), 0.87 (m, 1, methylene), 0.70 (m, 3, methylene)
Ij	7.82 (d, 1, $J = 8$, ArH), 6.70-7.50 (m, 3, ArH), 6.23 (br, 1, NH), 2.87 (m, 1, methine), 0.87 (m, 1, methylene), 0.73 (m, 3, methylene)
Ik	8.67 (br, 1, NH), ^b 8.00 (d, 1, $J = 8$, ArH), 7.30-7.87 (m, 3, ArH), 2.87 (m, 1, methine), 0.77 (m, 1, methylene), 0.58 (m, 3, methylene)
II	8.73 (br, 1, NH), ^b 8.33 (d, 2, $J = 8$, ArH), 8.03 (d, 2, $J = 8$, ArH), 2.87 (m, 1, methine), 0.80 (m, 1, methylene), 0.67 (m, 3, methylene)
IIa	7.72 (d, 2, $J = 8$, ArH), 7.12 (d, 2, $J = 8$, ArH), 6.76 (br, 1, NH), 5.73 (m, 1, =CH), 5.23 (d, $J = 8$, =CH ₂), 5.03 (m, =CH ₂), 4.03 (t, 2, $J = 5$, NCH ₂ -C=), 2.73 (s, 3, ArCH ₃)
IIb	6.80-8.00 (m, 4, ArH; + 1 NH), 5.74 (m, 1, =CH), 5.30 (d, $J = 8$, =CH ₂), 5.08 (m, =CH ₂), 4.07 (t, 2, $J = 5$, NCH ₂ -C=)
IIc	6.80-8.10 (m, 4, ArH), 7.47 (br, 1, NH), 5.67 (m, 1, =CH), 5.22 (d, $J = 8$, =CH ₂), 5.00 (m, =CH ₂), 4.00 (t, 2, $J = 5$, NCH ₂ -C=)
IId	7.20 (m, 4, ArH; + 1 NH), 5.63 (m, 1, =CH), 5.22 (d, $J = 10$, =CH ₂), 5.00 (m, =CH ₂), 3.89 (t, 2, $J = 5$, NCH ₂ -C=)
IIe	6.80-8.20 (m, 4, ArH; + 1 NH), 5.70 (m, 1, =CH), 5.27 (d, $J = 8$, =CH ₂), 5.03 (m, =CH ₂), 4.00 (t, 2, $J = 5$, NCH ₂ -C=)
IIf	7.77 (d, 2, $J = 8$, ArH), 7.30 (d, 2, $J = 8$, ArH; + 1 NH), 5.68 (m, 1, =CH), 5.25 (d, $J = 6$, =CH ₂), 5.03 (m, =CH ₂), 4.02 (t, 2, $J = 5$, NCH ₂ -C=)
IIg	7.25 (m, 4, ArH), 6.68 (br, 1, NH), 5.68 (m, 1, =CH), 5.28 (d, $J = 10$, =CH ₂), 5.07 (m, =CH ₂), 3.95 (t, 2, $J = 5$, NCH ₂ -C=)
IIh	7.20-8.30 (m, 4, ArH), 6.98 (br, 1, NH), 5.63 (m, 1, =CH), 5.27 (d, $J = 8$, =CH ₂), 5.03 (m, =CH ₂), 3.88 (t, 2, $J = 5$, NCH ₂ -C=)
IIi	8.23 (d, 2, $J = 8$, ArH), 7.90 (d, 2, $J = 8$, ArH), 6.87 (br, 1, NH), 5.72 (m, 1, =CH), 5.30 (d, $J = 8$, =CH ₂), 5.07 (m, =CH ₂), 4.07 (t, 2, $J = 5$, NCH ₂ -C=)
IIIa	7.37 (d, 2, $J = 8$, ArH), 7.17 (d, 2, $J = 8$, ArH), 5.65 (m, 2, =CH), 5.30 (s, =CH ₂), 5.08 (d, $J = 6$, =CH ₂), 4.00 (d, 4, $J = 5$, N(CH ₂ -C=) ₂), 2.35 (s, 3, ArCH ₃)
IIIb	7.37 (d, 2, $J = 8$, ArH), 6.80 (d, 2, $J = 8$, ArH), 5.60 (m, 2, =CH), 5.22 (s, =CH ₂), 5.00 (d, $J = 6$, =CH ₂), 3.92 (d, 4, $J = 5$, N(CH ₂ -C=) ₂), 3.65 (s, 3, ArOCH ₃)
IIIc	7.33 (m, 4, ArH), 5.62 (m, 2, =CH), 5.28 (s, =CH ₂), 5.07 (d, $J = 9$, =CH ₂), 3.95 (br, 4, N(CH ₂ -C=) ₂)
IIId	8.18 (d, 1, $J = 6$, ArH), 7.20-7.90 (m, 3, ArH), 4.70-6.40 (m, 6, =CH + =CH ₂), 4.18 (d, $J = 5$, N(CH ₂ -C=) ₂), 3.70 (d, $J = 5$, N(CH ₂ -C=) ₂)
IVa	6.50-8.20 (m, 9, ArH, A and B; + 1 NH), 4.62 (d, $J = 6$, NCH ₂ -Ar)
IVb	7.00-8.20 (m, 9, ArH, A and B), 6.87 (br, 1, NH), 4.42 (d, 2, $J = 6$, NCH ₂ -Ar)
Vb	6.80-7.70 (m, 14, ArH, A and B), 4.57 (br s, 4, N(CH ₂ -Ar) ₂), 2.32 (s, 3, ArCH ₃)
Ve	6.70-7.70 (m, 14, ArH, A and B), ^c 4.52 (br s, 4, N(CH ₂ -Ar) ₂)
Vf	6.70-7.70 (m, 14, ArH, A and B), 4.53 (br s, 4, N(CH ₂ -Ar) ₂)
VIa	7.00-8.00 (m, 15, ArH, A and B; + 1 NH), 6.48 (d, 1, $J = 8$, NCHAr ₂)
VIIb	7.80 (d, 2, $J = 8$, ArH, A), 7.28 (m, 10, ArH, B), 6.90 (d, 2, $J = 8$, ArH, A; + 1 NH), 6.43 (d, 1, $J = 8$, NCHAr ₂), 3.83 (s, 3, ArOCH ₃)
VIc	8.07 (m, 1, ArH, A), 7.27 (m, 13, ArH, A and B; + 1 NH), 6.50 (d, 1, $J = 8$, NCHAr ₂)
VIId	7.83 (m, 2, ArH, A), 6.80-7.40 (m, 12, ArH, A and B; + 1 NH), 6.40 (d, 1, $J = 8$, NCHAr ₂)
VIe	7.65 (m, 1, ArH, A), 7.28 (m, 13, ArH, A and B; + 1 NH), 6.43 (d, 1, $J = 8$, NCHAr ₂)
VIIf	7.73 (d, 2, $J = 8$, ArH, A), 7.27 (m, 12, ArH, A and B), 6.73 (br, NH), 6.37 (d, 1, $J = 8$, NCHAr ₂)
VIg	9.70 (d, 1, $J = 8$, NH), ^b 6.80-8.30 (m, 14, ArH, A and B), 6.33 (d, 1, $J = 8$, NCHAr ₂)
VIh	9.67 (d, 1, $J = 8$, NH), ^b 8.27 (m, 4, ArH, A), 7.33 (m, 10, ArH, B), 6.50 (d, 1, $J = 8$, NCHAr ₂)
VIIa	6.80-7.60 (m, 15, ArH, A and B; + 1 NH), 6.23 (s, 1, NCHAr ₂), 3.55 (s, 2, ArCH ₂ -CO)
VIIb	8.93 (d, 1, $J = 8$, NH), ^b 6.80-7.60 (m, 14, ArH, A and B), 6.17 (d, 1, $J = 8$, NCHAr ₂), 3.62 (s, 2, ArCH ₂ -CO), 2.25 (s, 3, ArCH ₃)
VIIc	8.97 (d, 1, $J = 8$, NH), ^b 6.80-7.60 (m, 14, ArH, A and B), 6.12 (d, 1, $J = 8$, NCHAr ₂), 3.50 (s, 2, ArCH ₂ -CO), 2.23 (s, 3, ArCH ₃)
VIIId	8.77 (d, 1, $J = 8$, NH), ^b 6.70-7.70 (m, 14, ArH, A and B), 6.20 (d, 1, $J = 8$, NCHAr ₂), 3.72 (s, 3, ArOCH ₃), 3.58 (s, 2, ArCH ₂ -CO)
VIIe	9.02 (d, 1, $J = 8$, NH), ^b 6.50-7.60 (m, 14, ArH, A and B), 6.20 (d, 1, $J = 8$, NCHAr ₂), 3.67 (s, 3, ArOCH ₃), 3.58 (s, 2, ArCH ₂ -CO)
VIIIf	6.70-7.50 (m, 14, ArH, A and B; + 1 NH), ^c 6.23 (s, 1, NCHAr ₂), 3.77 (s, 3, ArOCH ₃), 3.50 (s, 2, ArCH ₂ -CO)
VIIg	9.00 (d, 1, $J = 8$, NH), ^b 7.27 (m, 14, ArH, A and B), 6.18 (d, 1, $J = 8$, NCHAr ₂), 3.60 (s, 2, ArCH ₂ -CO)
VIIh	9.00 (d, 1, $J = 8$, NH), ^b 7.30 (m, 14, ArH, A and B), 6.17 (d, 1, $J = 8$, NCHAr ₂), 3.80 (s, 2, ArCH ₂ -CO)
VIIi	9.05 (d, 1, $J = 8$, NH), ^b 7.30 (m, 14, ArH, A and B), 6.18 (d, 1, $J = 8$, NCHAr ₂), 3.62 (s, 2, ArCH ₂ -CO)
VIIj	9.00 (d, 1, $J = 8$, NH), ^b 6.80-7.70 (m, 14, ArH, A and B), 6.20 (d, 1, $J = 8$, NCHAr ₂), 3.60 (s, 2, ArCH ₂ -CO)

^a Symbols: br = broad signal; br s = broad singlet; d = doublet; m = multiplet; s = singlet; t = triplet. ^b Measured in (CD₃)₂SO. ^c Spectrum obtained from a Varian Associates EM-390 instrument.

(to whom I am grateful). Unless otherwise mentioned, melting points were determined on a Kofler hot stage and are uncorrected. Infrared (IR) spectra were obtained on a Perkin-Elmer 257 grating spectrometer in Nujol mulls. Proton nuclear magnetic resonance (^1H NMR) spectra were measured on a Varian Associates T-60 instrument, in CDCl_3 . All peak positions were measured in ppm relative to tetramethylsilane (Me_4Si) as an internal standard ($\delta_{\text{Me}_4\text{Si}} = 0$). The J values are recorded in hertz. Yields were based on crystallization from benzene.

Acid Chloride Method. Typical Procedure 1. *N*-Allyl-3-chlorobenzamide (IIe). To a 50-mL dry benzene solution of 3-chlorobenzoyl chloride (17.5 g, 0.1 mol) was added cautiously, with stirring and cooling (ice bath), allylamine (11.4 g, 0.2 mol) in 50 mL of benzene over 0.5 h; the final solution was allowed to stir for 18 h. Workup as usual gave 19.1 g of crude and 15.8 g from benzene. (This procedure was used in the synthesis of the *N*-allyl and *N*-cyclopropyl compounds.)

Typical Procedure 2. *N*-Benzhydrylbenzamide (VIa). Benzoyl chloride (14.1 g, 0.1 mol) in 50 mL of dry benzene was treated likewise, as above, with benzhydrylamine (18.3 g, 0.1 mol) and 15.0 g of triethylamine dissolved in 50 mL of benzene. Workup as usual gave 30.1 g of crude and 26.3 g from acetone-benzene.

Thermal Method. Typical Procedure. *N*-Benzhydryl-4-chlorophenylacetamide (VIII). A mixture of 4-chlorophenylacetic acid (8.5 g, 0.05 mol), benzhydrylamine (9.2 g, 0.05 mol), and 50 mL of *o*-xylene was placed in a 100-mL round-bottomed flask equipped with a reflux condenser and a Dean-Stark apparatus and heated in an electrical heating mantle for 6 h when distillation of water ceased. Workup as usual gave 14.5 g of crude and 13.4 g from acetone-benzene.

Acknowledgment

I thank Mrs. Margaret Adams of the Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, and the Microanalytical Laboratory, University of Illinois, Urbana, for the microanalyses. I also thank Professor Peter Beak for granting technical facilities.

Registry No. Ia, 15205-35-3; Ib, 88229-12-3; Ic, 88229-13-4; Id, 88229-14-5; Ie, 88229-15-6; If, 88229-16-7; Ig, 88229-17-8; Ih,

39887-35-9; II, 88229-18-9; Ij, 88229-19-0; Ik, 88229-20-3; Il, 88229-21-4; Ila, 88229-22-5; Iib, 88229-23-6; Iic, 39887-14-4; IId, 66896-68-2; Iie, 35306-52-6; Iif, 5866-99-9; Iig, 88229-24-7; Iih, 88229-25-8; III, 88229-26-9; IIIa, 39108-89-9; IIIb, 39108-80-0; IIIc, 5867-01-6; IIId, 88229-27-0; IVa, 724-37-8; IVb, 52745-10-5; Va, 23825-35-6; Vb, 88229-28-1; Vc, 57409-26-4; Vd, 57409-28-6; Ve, 88229-29-2; Vf, 7465-70-5; Vg, 57409-24-2; Vh, 7461-37-2; Vi, 57409-27-5; Vj, 2585-27-5; VIa, 1485-72-9; VIb, 69790-46-1; VIc, 88229-30-5; VIId, 88229-31-6; VIe, 69790-47-2; VIi, 88229-32-7; VIg, 88229-33-8; VIh, 88229-34-9; VIIa, 10254-16-7; VIIb, 88229-35-0; VIIc, 88229-36-1; VIId, 88229-37-2; VIIe, 88229-38-3; VIIf, 88229-39-4; VIIg, 88229-40-7; VIIh, 88229-41-8; VIIi, 88229-42-9; VIIj, 88229-43-0; 3-chlorobenzoyl chloride, 618-46-2; benzoyl chloride, 98-88-4; 4-chlorophenylacetic acid, 1878-68-8; allylamine, 107-11-9; benzhydrylamine, 91-00-9.

Literature Cited

- (1) Agwada, V. C. *J. Chem. Eng. Data* 1982, 27, 479-81 (paper 1).
- (2) Agwada, V. C. *J. Chem. Eng. Data* 1982, 27, 481-3 (paper 2).
- (3) Roberts, J. D.; Chambers, V. C. *J. Am. Chem. Soc.* 1951, 73, 3178-9.
- (4) Hass, H. B.; Schechter, H. *J. Am. Chem. Soc.* 1953, 75, 1382-4.
- (5) Schlesinger, A. H.; Prill, E. J. *J. Am. Chem. Soc.* 1958, 80, 6123-7.
- (6) Shapiro, S. L.; Parrino, V. A.; Freedman, L. *J. Am. Chem. Soc.* 1959, 81, 3728-36.
- (7) Pagani, G.; Beruffini, A.; Caccialanza, G.; Calderara, G. *Farmaco, Ed. Sci.* 1971, 26, 821-43.
- (8) Behrens, O. K.; Corse, J.; Huff, D. E.; Jones, R. G.; Soper, Q. F.; Whitehead, C. W. *J. Biol. Chem.* 1948, 175, 771-92.
- (9) Joshi, K. C.; Giri, S. *J. Ind. Chem. Soc.* 1960, 37, 423-4.
- (10) Ragini, A.; Khara, S. S. *Can. J. Chem.* 1960, 38, 746-8.
- (11) Wittig, G.; Ludwig, H. *Justus Liebig's Ann. Chem.* 1954, 589, 55-76.
- (12) Chierici, L.; Passerini, R. *J. Chem. Soc.* 1954, 3249-50.
- (13) Prasnar, B.; Troszkiewicz, C. *Rocz. Chem.* 1962, 36, 1029-38.
- (14) Lewin, A. H.; Frucht, M. *Org. Magn. Reson.* 1975, 7, 206-25.
- (15) Cohen, T.; Moran, R. M.; Sowinski, G. *J. Org. Chem.* 1961, 26, 1-5.
- (16) Zinner, G. *Arch. Pharm. Chem.* 1963, 296, 420-6.
- (17) Hohenlohe-Oehringen, K. *Monatsh. Chem.* 1962, 93, 639-44.
- (18) Skulski, L.; Palmer, G. C.; Calvin, M. *Rocz. Chem.* 1964, 38, 789-809.
- (19) Sanguigni, J. A.; Levine, R. *J. Med. Chem.* 1964, 7, 573-4.
- (20) Cheeseman, G. W. H.; Poller, R. C. *Analyst (London)* 1962, 87, 366-8.
- (21) Christol, H.; Laurent, A.; Solladie, G. *Bull. Soc. Chim. Fr.* 1963, 877-81.

Received for review April 4, 1983. Revised manuscript received July 19, 1983. Accepted August 9, 1983. I am indebted to the University of Nigeria, Nsukka, for financial assistance.

Potential Central Nervous System Active Agents. 4. Synthesis of *N*-Isobutylbenzamides

Vincent C. Agwada*

Department of Chemistry, Faculty of Physical Sciences, University of Nigeria, Nsukka, Nigeria

Peter Beak

School of Chemical Sciences, Department of Chemistry, Roger Adams Laboratory, University of Illinois, Urbana, Illinois 61801

The preparation and spectral properties (IR, ^1H NMR) are given for 11 *N*-isobutylbenzamides, variously substituted on the acyl part with halo, methoxyl, methyl, or nitro groups, including two new ones. The amides were synthesized by the Schotten-Baumann method in anhydrous benzene.

In the preceding communications (1-3), the synthesis and the spectroscopic data (IR, mass spectra, ^1H NMR) of some

substituted benzamides and phenylacetamides were reported. As part of a general study of the structure-activity relationship in the central nervous system active compounds, 11 *N*-isobutylbenzamides, variously substituted on the acyl part with halo, methoxyl, methyl, or nitro groups, were synthesized by the Schotten-Baumann method in anhydrous benzene. Compounds 4 and 9 are new. The spectroscopic data (IR, ^1H NMR) not hitherto described in the literature are reported in this communication.

The experimental and IR data on all of the compounds are summarized in Table I, and those of the ^1H NMR spectral data